AZA Combined With RCHOP in P53-mutated DLBCL.
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorThe First Affiliated Hospital of Xiamen University
About this trial
To evaluate the efficacy and adverse effects of Azacitidine in combination with R-CHOP (ARCHOP) for the treatment of TP53-mutated previously untreated Diffuse large B-cell lymphoma
Eligibility criteria
Qualifiers
None
Disqualifiers
Primary and secondary central DLBCL;
HIV-positive patients and or HCV active infection; (3) Clinically significant secondary cardiovascular disease;
Trial design
Treatments tested in this trial
- Azacitidine in combination with R-CHOP
Treatment groups
52 Participants
are divided into 1 treatment groupSponsors and collaborators
The First Affiliated Hospital of Xiamen University
Lead sponsor
Jiangsu Provincial People's Hospital
Collaborator
Sun Yat-sen University
Collaborator
Chinese Academy of Medical Sciences
Collaborator
Shanxi Province Cancer Hospital
Collaborator
Source ClinicalTrials.gov